vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and MARRIOTT VACATIONS WORLDWIDE Corp (VAC). Click either name above to swap in a different company.
MARRIOTT VACATIONS WORLDWIDE Corp is the larger business by last-quarter revenue ($1.2B vs $1.2B, roughly 1.0× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -35.0%, a 52.0% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -0.7%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $-6.0M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 5.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Marriott Vacations Worldwide Corporation is a pure-play public timeshare company. Formerly a division of Marriott International, Marriott Vacations Worldwide was established as a separate, publicly traded entity focusing primarily on vacation ownership in November 2011. Marriott Vacations Worldwide runs more than 120 resorts with over 700,000 Owners and members in a diverse portfolio of brands under The Marriott Vacation Clubs name. Its brands include Marriott Vacation Club, The Marriott Vaca...
JAZZ vs VAC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.2B |
| Net Profit | $203.5M | $-431.0M |
| Gross Margin | — | — |
| Operating Margin | 21.2% | — |
| Net Margin | 17.0% | -35.0% |
| Revenue YoY | 10.1% | -0.7% |
| Net Profit YoY | 6.5% | -962.0% |
| EPS (diluted) | $3.34 | $-12.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $897.8M | $1.1B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $902.0M | $1.1B |
| Q4 25 | $203.5M | $-431.0M | ||
| Q3 25 | $251.4M | $-2.0M | ||
| Q2 25 | $-718.5M | $69.0M | ||
| Q1 25 | $-92.5M | $56.0M | ||
| Q4 24 | $191.1M | $50.0M | ||
| Q3 24 | $215.1M | $84.0M | ||
| Q2 24 | $168.6M | $37.0M | ||
| Q1 24 | $-14.6M | $47.0M |
| Q4 25 | 21.2% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -65.6% | — | ||
| Q1 25 | -6.2% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 7.3% | — |
| Q4 25 | 17.0% | -35.0% | ||
| Q3 25 | 22.3% | -0.2% | ||
| Q2 25 | -68.7% | 6.0% | ||
| Q1 25 | -10.3% | 5.0% | ||
| Q4 24 | 17.6% | 4.0% | ||
| Q3 24 | 20.4% | 6.9% | ||
| Q2 24 | 16.5% | 3.5% | ||
| Q1 24 | -1.6% | 4.2% |
| Q4 25 | $3.34 | $-12.00 | ||
| Q3 25 | $4.08 | $-0.07 | ||
| Q2 25 | $-11.74 | $1.77 | ||
| Q1 25 | $-1.52 | $1.46 | ||
| Q4 24 | $2.97 | $1.29 | ||
| Q3 24 | $3.42 | $2.12 | ||
| Q2 24 | $2.49 | $0.98 | ||
| Q1 24 | $-0.23 | $1.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $406.0M |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $2.0B |
| Total Assets | $11.7B | $9.8B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $406.0M | ||
| Q3 25 | $1.3B | $474.0M | ||
| Q2 25 | $1.2B | $205.0M | ||
| Q1 25 | $1.9B | $196.0M | ||
| Q4 24 | $2.4B | $197.0M | ||
| Q3 24 | $2.2B | $197.0M | ||
| Q2 24 | $1.4B | $206.0M | ||
| Q1 24 | $1.4B | $237.0M |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $2.0B | ||
| Q3 25 | $4.0B | $2.5B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $4.2B | $2.4B | ||
| Q4 24 | $4.1B | $2.4B | ||
| Q3 24 | $4.2B | $2.4B | ||
| Q2 24 | $3.8B | $2.4B | ||
| Q1 24 | $3.7B | $2.4B |
| Q4 25 | $11.7B | $9.8B | ||
| Q3 25 | $11.4B | $10.1B | ||
| Q2 25 | $10.9B | $9.9B | ||
| Q1 25 | $11.5B | $9.9B | ||
| Q4 24 | $12.0B | $9.8B | ||
| Q3 24 | $12.3B | $9.7B | ||
| Q2 24 | $11.4B | $9.6B | ||
| Q1 24 | $11.3B | $9.9B |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $6.0M |
| Free Cash FlowOCF − Capex | $345.8M | $-6.0M |
| FCF MarginFCF / Revenue | 28.9% | -0.5% |
| Capex IntensityCapex / Revenue | 1.4% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $-29.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $6.0M | ||
| Q3 25 | $474.6M | $62.0M | ||
| Q2 25 | $88.9M | $-48.0M | ||
| Q1 25 | $429.8M | $8.0M | ||
| Q4 24 | $398.6M | $100.0M | ||
| Q3 24 | $398.7M | $72.0M | ||
| Q2 24 | $331.4M | $30.0M | ||
| Q1 24 | $267.2M | $3.0M |
| Q4 25 | $345.8M | $-6.0M | ||
| Q3 25 | $459.4M | $51.0M | ||
| Q2 25 | $75.9M | $-68.0M | ||
| Q1 25 | $415.9M | $-6.0M | ||
| Q4 24 | $385.3M | $86.0M | ||
| Q3 24 | $388.0M | $58.0M | ||
| Q2 24 | $324.3M | $17.0M | ||
| Q1 24 | $260.3M | $-13.0M |
| Q4 25 | 28.9% | -0.5% | ||
| Q3 25 | 40.8% | 4.3% | ||
| Q2 25 | 7.3% | -5.9% | ||
| Q1 25 | 46.3% | -0.5% | ||
| Q4 24 | 35.4% | 6.9% | ||
| Q3 24 | 36.8% | 4.8% | ||
| Q2 24 | 31.7% | 1.6% | ||
| Q1 24 | 28.9% | -1.2% |
| Q4 25 | 1.4% | 1.0% | ||
| Q3 25 | 1.3% | 0.9% | ||
| Q2 25 | 1.2% | 1.7% | ||
| Q1 25 | 1.5% | 1.3% | ||
| Q4 24 | 1.2% | 1.1% | ||
| Q3 24 | 1.0% | 1.1% | ||
| Q2 24 | 0.7% | 1.2% | ||
| Q1 24 | 0.8% | 1.4% |
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | -0.70× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | 2.09× | 2.00× | ||
| Q3 24 | 1.85× | 0.86× | ||
| Q2 24 | 1.97× | 0.81× | ||
| Q1 24 | — | 0.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
VAC
| Cost Reimbursement | $467.0M | 38% |
| Time Share | $381.0M | 31% |
| Management And Exchange | $212.0M | 17% |
| Ancillary Revenues | $64.0M | 5% |
| Management Service | $55.0M | 4% |
| Service Other | $36.0M | 3% |
